Beleodaq (belinostat) / Valerio Therap, Aurobindo, Assertio - LARVOL DELTA

Profiling drug sensitivity in CLL B cells after BTK inhibitor progression using a novel drug panel (ASH 2025) - " Using the Mayo Clinic CLL Database and the Mayo Clinic CLL Tissue Bank, we identified 47 patients with RR CLL, all of whom experienced disease progressionon a BTKi (35 ibrutinib +/- CD20 antibody, 10 acalabrutinib +/- CD20 antibody, 2 other)...We also observed that RR CLL cohort exhibited significantly increased drug resistance to most of the tested drugs in the presence of BMSCs with corresponding increases in IC50s (with vs. without BMSCs, fold-change respectively): LP-118 3.92-fold, venetoclax 1.98-fold, carfilzomib 2.58-fold, TP-0903 1.65-fold, panobinostat 204.23-fold, TCIP1 1.91-fold, crenolanib 1.31-fold, idasanutlin 1.69-fold, belinostat 6.14-fold, LP-168 1.29-fold, eprenetapopt 3.44-fold and GTE 1.08-fold (11 out of 12 with p -values <0.05 except for GTE which was not significant, Mann-Whitney U test)... Our results highlight the spectrum of currently available drugs that show promise for therapeutic use in patients with RR CLL who experience disease..."

IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • AXL • BCL2 • STAT6 • TP53

Survival and response rates of histone deacetylase inhibitors in peripheral T-cell lymphoma: A comprehensive systematic review and meta-analysis of 67 studies. (ASH 2025) - "It has high relapses and unfavorable prognoses with first-line chemotherapy regimens (cyclophosphamide, doxorubicin, vincristine, and prednisone)...Currently, romidepsin, vorinostat, and belinostat have US FDA approval for the treatment of relapsed/refractory PTCL, while chidamide is approved in China but is not approved in the US...HDACi monotherapy in patients with R/R T cell lymphoma, demonstrated an ORR, with chidamide [42%; 95% CI: (0.148, 0.57), p-value = <0.00001, I2=85%] followed by romidepsin [30%; 95% CI: (0.25, 0.35), p-value = <0.00001, I2=35%], abexinostat [28%; 95% CI: (0.19, 0.37), p-value = <0.00001], belinostat [26%; 95% CI: (0.19, 0.33), p-value = <0.00001, I2=0%]... This meta-analysis demonstrates that HDACi has shown overall improved response rates and survival in PTCL patients. However, chidamide has higher response rates than romidepsin in previously treated (UT) patients. In R/R patients, complete remission is higher with romidepsin;..."

Epigenetic controller • Retrospective data • Review • Adult T-Cell Leukemia-Lymphoma • Extranodal Natural Killer/T-cell Lymphoma • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ALK

Efficacy of novel agents in the treatment of acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis (ASH 2025) - "Newer agents included for AML were Guadectiabine, Magrolimab, Alvocidib, Enasidenib, Flotetuzumab, Vadastuximab, Mitoxantrone, Pevonedistat, Entospletinib, Eprenetapopt, Belinostat, Onvansertib, Panobinostat, Cediranib Maleate, Nilotinib, Emavusertib, and anti-CD45 antibody (DOTA-BC8). The newer agents investigated for MDS included Rigosertib, Imetelstat, Pembrolizumab, Enasidenib, Sabatolimab, Ivosidenib, Elitercept, Pevonedistat, Emavusertib, Atezolizumab, and Olutasidenib...All patients were treated concomitantly with either azacitidine (77%) or decitabine (23%)... This meta-analysis and systematic review demonstrate promising efficacy for novel agents in AML and MDS patients. There is a need for prospective trials with larger patient populations to investigate these agents further."

Retrospective data • Review • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Neutropenia • TP53

The NLP protein is a novel regulator of G2-m Phase of the cell cycle critical for proliferation of human peripheral T-cell lymphomas (ASH 2025) - "Standard regimens such as CHOP or R‑CHOP, along with approved targeted agents(belinostat, romidepsin, pralatrexate), have yielded limited long‑term benefit, with 5‑year survival rates ofonly 20–30%...Homozygous NLP knockout mice are viable butshow ~10% reduction in the body size suggesting that mouse NLP is important but not essential fornormal development.Altogether, our findings identify NLP as a novel regulator of the G2–M phase of the cell cycle with acritical role in the proliferation of malignant T-cells. Given its predicted druggable structure, NLPrepresents a promising candidate for the development of novel targeted PTCL therapies."

Hematological Malignancies • Liver Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Renal Cell Carcinoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma • ATF5 • BRCA1 • CHEK2 • EPAS1 • RPL10

A Phase II, single-center, single-arm study evaluating the safety and efficacy of golidocitinib in the management of newly diagnosed PTCL (GOLDEN Study) (ASH 2025) - P2 | "Background First-line (1L) therapy for peripheral T-cell lymphoma (PTCL) is cyclophosphamide, doxorubicin, vincristineand prednisone (CHOP)-based, and relapse/refractory (r/r) rates are high (75%) with limited therapeuticoptions thereafter; currently approved agents for r/r PTCL include belinostat and pralatrexate, withoverall response rates (ORR) of <30% and progression free survival (PFS) between 2-4 months. To our knowledge, this study is thefirst to explore a novel oral targeted agent for newly diagnosed pts with a subtype specific PTCL. Thechemotherapy de-escalation and response-adapted design will potentially identify pts who may benefitfrom no chemotherapy or novel agent plus chemotherapy combination."

Clinical • P2 data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • JAK1

Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL) (ASH 2025) - P1, P3 | "Introduction ITK is expressed in T cells and NK cells and is involved in multiple signaling pathways including T cellreceptor (TCR) activation and differentiation of T helper (Th) cells. Thesefindings indicate that the mechanism of action involves the induction of a host anti-tumor immuneresponse that requires a baseline level of immunocompetence. These data suggest that effectivetherapeutic strategies for these lymphomas should extend beyond direct targeting of malignant T cells.SQL is now being evaluated vs standard therapy (belinostat or pralatrexate) in a randomized Phase 3registration trial in PTCL pts with 1-3 prior therapies (NCT06561048)."

Clinical • IO biomarker • P1 data • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Pruritus • CD4 • CD8 • GATA3 • HAVCR2 • IFNG • IL2 • ITK • LAG3 • TNFA

A Phase 2 trial of AI-BEL (AZT/Interferon-α plus Belinostat) for HTLV-1 related adult T-cell leukemia-lymphoma: Final safety and efficacy Results (ASH 2025) - "Our pre-clinical work using patient derived ATL modelsdemonstrated that belinostat (BEL), a pan-HDAC inhibitor, reactivates HTLV-1 (Tax protein) expressionin ATL cells in a dose-dependent manner, an effect that was augmented by azidothymidine (AZT, orzidovudine). AI-BEL showed good efficacy in patients with aggressive ATL resulting in CMR in blood compartment,which occured after treatment discontinuation in multiple subjects. The overall results comparefavorably to those observed in historical trials for ATL that included previously treated or relapsedpatients. Judicious use of HDAC inhibitors in combination with AZT/interferon-α based treatment canprovoke sustained immunologic effects resulting in deep molecular responses."

Clinical • P2 data • Adult T-Cell Leukemia-Lymphoma • Agranulocytosis • Febrile Neutropenia • Granulocytopenia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CD8

Dual HDAC and EZH2 inhibition modulates RFX5 activity to increase the immunogenicity of germinal center-derived B-cell lymphoma (ASH 2025) - P1 | "Belinostat (BEL), an HDAC inhibitor, and tazemetostat (TAZ), an EZH2inhibitor, counteract the epigenetic derangements caused by CREBBP and EZH2 mutations, and togetherincrease immune activity and antigen presentation targets to create a "hot" tumor environment. RFX5 expression was knocked down (KD) in SU-DHL-4 cells usingsiRNAs. RFX5 WT and KD cells were treated with vehicle, BEL, TAZ, or BEL+TAZ for six days and co-cultured with T cells for 24 h. Decreased cell viability was observed in the RFX5 WT cells but not the KDsfollowing treatment (n=3), revealing the critical role of RFX5 expression in BEL+TAZ-mediated cell kill.Lastly, RFX5 knockout (KO) murine A20 lymphoma cells were generated using CRISPR-Cas9 gene editing.An experiment is currently underway evaluating tumor growth and overall survival in vehicle-, BEL-, TAZ-,and BEL+TAZ-treated BALB/c mice xenografted with either RFX5 WT or KO murine A20 cells.In conclusion, dual HDAC and EZH2 inhibition..."

B Cell Lymphoma • Gene Therapies • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • B2M • CD4 • CD8 • CREBBP • HLA-DQA1 • HLA-DRA • TAFAZZIN

Humanized PDX models reveal Lymphoma–Host interactions and enhanced T-cell therapies via epigenetic modulation (ASH 2025) - "To explore this complex ecosystem,we analyzed DLBCL biopsies from patients receiving chemotherapy (R-CHOP) or immunotherapy(chimeric antigen receptor CAR T cells) using integrated omics and functional assays, together with fullyhumanized mouse models (HuMice). We analyzed 68 DLBCL cases (48 post R-CHOP and 20 post CAR T-cell–treated) and 48 matchedpatient-derived xenografts (PDX) by bulk RNA-seq, single-cell RNA/TCR-seq, and WES/CAPP-seq...However, splenic T-cells from IR-DLBCL-HuPDX exhibited strong proliferation, clonal expansion, and cytotoxicity against matched tumors.To enhance responses in ID-DLBCL-HuPDX, we performed dose-response screens of single- and dual-drug combinations using clinical phase compounds shown to improve immune responses (e.g.,valemetostat, DNMT1i, GSK-3685032, azacytidine, belinostat, romidepsin, and lenalidomide) and identifysynergistic associations (Vale+GSK, Vale+ Lena: Synergy Score >20)... Epigenetic therapies reprogram the..."

IO biomarker • IO Companion diagnostic • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gene Therapies • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • CD34 • CD8 • DNMT1 • IFNG • TNFA

The Pharmacological Atlas of Meningiomas (SNO 2025) - "The top five drugs with the lowest IC50 values were romidepsin, dactinomycin, carfilzomib, plicamycin, and omacetaxine, with median values of 10, 31, 145, 303, and 400 nM, respectively. Considering the ratio of peak serum concentration (Cmax) to IC50 as a potential predictor of treatment efficacy (>1), the HDAC inhibitors belinostat (74.5), romidepsin (69.7), along with the proteasome inhibitor carfilzomib (34.6), and the anthracyclines epirubicin (2.6), and doxorubicin (1.8), and the PI3K inhibitor idelalisib (1.6) are the most promising drug candidates for further evaluation. This study offers the first comprehensive insight into the pharmacological landscape of meningiomas, providing a crucial foundation for future clinical trials aimed at developing systemic treatments for aggressive meningiomas."

Brain Cancer • Meningioma • Solid Tumor

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) (clinicaltrials.gov) - P3 | N=218 | Recruiting | Sponsor: Dizal Pharmaceuticals

New P3 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

SINGLE CELL SEQUENCING ENABLES LINEAGE-INFORMED TARGETING OF OSTEOSARCOMA (CTOS 2025) - "Stem-like lines were differentially sensitive to refametinib (IC50 range: 1.37 - 66.0 µM), a MEK inhibitor, consistent with MAPK pathway dependence. Our single-cell atlas offers a foundation for lineage-specific therapeutic targeting and disease monitoring. Expanded drug screening and larger-scale in vivo validation studies are needed to inform future precision strategies in OS."

Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Proteome-wide multi-trait association analyses prioritize candidate proteins and therapeutic targets for psychiatric disorders. (PubMed, J Affect Disord) - "Drug repurposing analyses nominated 32 compounds, including belinostat and vorinostat, that counteract risk-associated expression patterns, alongside 164 clinically actionable drug-protein interactions. Our study provides a mechanistic framework linking genetic risk to brain protein dysregulation and proposes tractable therapeutic targets for psychiatric disorders."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • Schizophrenia

The Pharmacological Atlas of Meningiomas (WFNOS 2025) - "The top five drugs with the lowest IC50 values were romidepsin, dactinomycin, carfilzomib, plicamycin, and omacetaxine, with median values of 10, 31, 145, 303, and 400 nM, respectively. Considering the ratio of peak serum concentration (Cmax) to IC50 as a potential predictor of treatment efficacy (>1), the HDAC inhibitors belinostat (74.5), romidepsin (69.7), along with the proteasome inhibitor carfilzomib (34.6), and the anthracyclines epirubicin (2.6), and doxorubicin (1.8), and the PI3K inhibitor idelalisib (1.6) are the most promising drug candidates for further evaluation. This study offers the first comprehensive insight into the pharmacological landscape of meningiomas, providing a crucial foundation for future clinical trials aimed at developing systemic treatments for aggressive meningiomas."

Brain Cancer • Meningioma • Solid Tumor

First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL (ASH 2023) - "In addition, we generated a belinostat-resistant H9 cell line (H9-belino-R) by incrementally exposing H9 to increasing concentrations of belinostat...H9-belino-R retained significant resistance to other HDAC inhibitors such as romidepsin [(H9: IC50 = 0.97nM (SEM ± 0.030), H9-belino-R: IC50 = 1.38nM (SEM ± 0.028)] and panobinostat [H9: IC50 = 3.11nM (SEM ± 0.19), H9-belino-R: IC50 = 9.00nM (SEM ± 1.55)] as measured by the CellTiter-Glo Viability Assay...These preliminary findings provide us with evidence that suggests that the combination of YF2 and ruxolitinib can serve as a novel treatment combination for CTCL. Further study is planned to explore this treatment in murine models of disease."

IO biomarker • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • ANXA5 • BAK1 • BCL2 • BCL2L1 • JAK1

Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma (ASH 2023) - "Other epigenetic therapies, such as tazemetostat and belinostat, are approved for use in follicular and T-cell lymphoma, respectively, but have limited single agent activity in DLBCL. In summary, these data propose YF2 combination epigenetic therapy as a means to increase immunogenicity in CBP/p300- and EZH2-mutated DLBCL. While our preliminary mouse experiment provided promising initial results, an expanded study is underway to statistically confirm the exciting trends that we observed."

Epigenetic controller • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gene Therapies • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • B2M • CD4 • CD8 • CREBBP

GATA-3 Dependent Gene Transcription Is Impaired upon HDAC Inhibition (ASH 2023) - "Among the 5,510-6,811 transcripts that were differentially expressed upon either belinostat or romidepsin treatment, respectively, ≈6-7% of transcripts were GATA-3 targets. Collectively, these findings demonstrate that GATA-3 hyperacetylation upon HDAC inhibition significantly impairs GATA-3 DNA binding and GATA-3 dependent gene transcription. Impact: GATA-3 and its target genes identify clinically and transcriptionally distinct T-cell lymphomas, including CTCL, that are resistant to conventional chemotherapeutic agents and generally associated with dismal outcomes. Therefore, GATA-3 is a rational, albeit challenging, therapeutic target in these T-cell lymphomas."

Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • GATA3 • HDAC1 • HDAC2 • MYC

C17ORF58 Is Upregulated in Peripheral T-Cell Lymphomas and Encodes a Protein Critical for Survival of PTCL Cells (ASH 2023) - "Despite the increase in specific T-cell lymphoma treatment options, such as belinostat, romidepsin, pralatrexate, and brentuximab vedotin, alongside conventional non-targeted chemotherapy like CHOP and R-CHOP, the overall 5 year survival remains only at 20-30%. In conclusion, our data indicate that upregulation of C17ORF58 may contribute to the progression and maintenance of PTCL and could serve as a potential target for treating T-cell malignancies. Investigations into its physiological role in normal T-cells and pathways deregulated upon its inactivation are ongoing."

B Cell Lymphoma • Cutaneous T-cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • COL1A2 • MYBL2 • PAX2 • TRIP13

Trial in Progress: A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-Cop to the CHOP Regimen Alone in Newly Diagnosed Patients with Peripheral T- Cell Lymphoma - Crescendo (ASH 2024) - P3 | "We anticipate enrolling 504 patients who meet the inclusion criteria : 18yrs with newly diagnosed, previously untreated PTCL (including PTCL-NOS, angioimmunoblastic T-cell lymphoma, ALK- negative ALCL [for which brentuximab vedoitin (Bv) cannot be used due to unavailability or tolerance], follicular T cell lymphoma and others [extra-nodal natural killer/T-cell lymphoma, nasal type; enteropathy-associated T-cell lymphoma; hepatosplenic T-cell lymphoma; and subcutaneous panniculitis-like T-cell lymphoma]) based on local pathology review, with measurable disease, ECOG performance status ≤2, and eligible to receive Bel or Fol, and a standard CHOP regimen (cyclophosphamide 750 mg/m2 IV, Day 1; doxorubicin 50 mg/m2 IV, Day 1; vincristine 1.4 mg/m2 (maximum 2 mg) IV, Day 1; and prednisone 100 mg daily PO, Days 1–5). Tumor assessments will be performed every 3 cycles and end-of-treatment visit, then every 3 months for 3 years for patients with CR, PR or SD, and every 6..."

Clinical • P3 data • Bone Marrow Transplantation • Cutaneous T-cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Hepatosplenic T-cell Lymphoma • Lymphoma • Mucositis • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

An Anti-Apoptotic Protein C17ORF58 Is Critical for the Maintenance of Human Peripheral T-Cell Lymphomas By Suppressing BBC3-Induced Apoptosis (ASH 2024) - "Despite treatments with conventional chemotherapy like CHOP and R-CHOP, as well as targeted therapies such as belinostat, romidepsin, pralatrexate, and brentuximab vedotin, the overall 5-year survival rate remains low at 20-30%. Consistently, C17ORF58 knockdown in T-cell lines results in the upregulation of numerous pro-apoptotic genes, including BBC3 (PUMA), EPAS1, ATF5, DUSP8, S100A6, and CHAC1. Importantly, shRNA-mediated knockdown of BBC3 suppresses apoptosis induced by C17ORF58 loss of function, suggesting that BBC3 is a key downstream target negatively regulated by C17ORF58.Altogether, our data suggest that C17ORF58 is an anti-apoptotic protein exerting its activity by suppressing BBC3-induced apoptosis, presenting a potential novel target for improving PTCL therapies."

Clinical • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • ATF5 • BBC3 • CHAC1 • DNMT3A • EPAS1 • S100A6

First Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Belinostat in Patients with R/R PTCL in Brazil (BELBRA) (ASH 2024) - "The study reports a 45% overall response rate, stable disease in 10%, and disease progression in 45% of the detailed cohort, with treatments being well tolerated across an average of 5 cycles. No other AE´s than the Belief Study was observed.Conclusion : These findings highlight Belinostat's potential as a favorable option for PTCL patients resistant to previous treatments, contributing as valuable real-world evidence to these challenging patients."

Clinical • Hematological Malignancies • Lymphoma • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma

Identifying Novel Epigenetic Therapies for T-Cell Lymphomas By High Throughput Drug Screen (ASH 2024) - "Introduction : Epigenetic alterations are known to contribute to development of T-cell lymphomas (TCL), and numerous epigenetic modifiers have shown safety and clinical efficacy in TCL leading to FDA approval of three histone deacetylase inhibiters (vorinostat, romidepsin, and belinostat)...At the conclusion of this screen, we tested cytotoxicity of our most encouraging compound in combination with other top performing compounds.Results : We identified BI-847325, bortezomib, camptothecin, CUDC-907, and WAY-118959-A as the most encouraging cytotoxic compounds that are not currently being used clinically. We compared the top 5 compounds to 4 standard of care (SOC) cytotoxic drugs (belinostat, gemcitabine, romidepsin, and vincristine) that are used clinically...We tested cytotoxicity of camptothecin in combination with 5 compounds (belinostat, bortezomib, BI-847325, romidepsin, and vincristine) that also demonstrated cytotoxicity in the malignant T-cells with relative..."

Cutaneous T-cell Lymphoma • Gene Therapies • Hematological Malignancies • Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma • ANXA5

Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma (ASH 2024) - P1 | "Once the RP2D is established, the study will enroll an expanded cohort of LBCL stratified by EZH2 mutation status. The hope is to create a strategy to target discrete mutations, like EZH2, EP300 and CREBBP, driving GC-derived lymphomas."

P1 data • Anemia • Cardiovascular • Diffuse Large B Cell Lymphoma • Gene Therapies • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Hypertension • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Otorhinolaryngology • Respiratory Diseases • Sinusitis • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Ventricular Tachycardia • CREBBP • EP300 • EZH2

Safety and Efficacy of AZT-Interferon-α with Belinostat (AI-BEL) for HTLV-1 Related Adult T-Cell Leukemia-Lymphoma (ASH 2024) - P2 | "The anti-ATL effects of BEL is augmented by AZT (zidovudine). AI-BEL is relatively safe to administer; however, hematologic adverse events are expected, which may warrant dose and treatment schedule modifications. Our clinical data support testing such approach in larger studies including as upfront therapy for ATL."

Clinical • IO biomarker • Adult T-Cell Leukemia-Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • CD8 • PD-1 • TIGIT

Dual HDAC and EZH2 Inhibition Primes Mosunetuzumab for the Treatment of Germinal Center-Derived B-Cell Lymphoma (ASH 2024) - P1 | "Belinostat (BEL), an HDAC inhibitor, and tazemetostat (TAZ), an EZH2 inhibitor, counteract the epigenetic derangements caused by CREBBP and EZH2 mutations. In conclusion, dual BEL+TAZ treatment increases MHC/CD20 expression on malignant B cells and activates peripheral T cells, priming the tumor microenvironment for MOSUN therapy. Taken together, our findings support dual HDAC and EZH2 inhibition as a potential means to prime immunotherapy and improve outcomes in GCB lymphomas."

IO biomarker • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Gene Therapies • Hematological Malignancies • Immune Modulation • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • B2M • CD44 • CD69 • CD8 • CREBBP • GZMA • GZMB • IL2RA • IL6